cancer therapy induced thrombocytopenia
Conditions
Interventions
Treatment Group:Romiplostim was given subcutaneously once a week at a dose of 3µg/kg.
Sponsors
The First Affiliated Hospital of Zhejiang Chinese Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old, regardless of gender; 2. CTIT(tumor drug-related thrombocytopenia, platelet count < 100×10^9/L) occurred after treatment of solid tumors, which led to the delay and reduction of chemotherapy; 3. At least 14 days after the last chemotherapy; 4. ECOG PS score 0-2; 5. Understand the study procedure and sign the informed consent form in person.
Exclusion criteria
Exclusion criteria: 1. Malignant tumor with bone marrow metastasis; 2. Patients with hematological malignancies; 3. Hemoglobin concentration below 80g/L after blood transfusion or neutrophil count below 1.0×10^9/L despite administration of granulocyte colony-stimulating factor (long or short acting); 4. Aspartate aminotransferase (AST) greater than 3.0×ULN (no liver metastasis); Aspartate aminotransferase (AST) > 5.0×ULN (liver metastasis); Total bilirubin > 1.5×ULN (no liver metastasis); Total bilirubin > 3.0×ULN (liver metastasis); 5. Deep vein thrombosis or arterial thrombosis within 3 months (except those who were stable and receiving anticoagulant or antiplatelet therapy); 6. It is known to be poorly responsive to TPO receptor agonists; 7. Pregnant or lactating patients; 8. Important organ dysfunction such as liver and kidney failure; 9. Other conditions considered by the investigator to be inappropriate for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recovery rate of platelet count; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event incidence rate; | — |
Countries
China
Contacts
Public ContactYe Baodong
The First Affiliated Hospital of Zhejiang Chinese Medical University
Outcome results
None listed